Stay updated with breaking news from Subsequent Highlights. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Achieved net revenue of $8.9 million for the three months ended March 31, 2024Adjusted EBITDA1 loss of $0.4 million for the three months ended March 31, 2024Negative operating cash flow of $0.9...
06.05.2024 - - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for ...
Anebulo Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse , today announced...
Anebulo Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or "Anebulo"), today announced financial results...